MedTrace Logo

Etanercept Plus Methotrexate Versus Methotrexate Alone in Children With Polyarticular Course Juvenile Rheumatoid Arthritis

NCT03781375 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2019-08-02

Study results available
· View outcomes & findings →

Summary

The primary objective of this study was to determine the efficacy of etanercept plus methotrexate vs methotrexate alone in pediatric patients with active polyarticular course juvenile rheumatoid arthritis (JRA).

Conditions

  • Juvenile Rheumatoid Arthritis

Interventions

DRUG

Etanercept

Administered by subcutaneous injection twice a week

DRUG

Placebo to Etanerceot

Administered by subcutaneous injection twice a week

DRUG

Methotrexate

Administered orally or subcutaneously once a week at the same dose as prior to study entry

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Sex
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-08-24
Primary Completion
2002-06-20
Completion
2002-06-24
FDA Drug
Yes

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03781375 on ClinicalTrials.gov